https://www.selleckchem.com/products/AT9283.html
to discontinuation in 15 (8%) versus 17 (14%) patients. Fatal TEAEs during study treatment occurred in six (3%) versus four (3%) patients. The addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population. Sanofi. VIDEO ABSTRACT. Sanofi. VIDEO ABSTRACT. Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult p
Aimer
Commentaire
Partagez
